Relmada Therapeutics Appoints Molly Harper as Executive Vice President of Operations

Previous PostRelmada Therapeutics Announces Outcome of End-of-Phase 2 Meeting with FDA for REL-1017 for Adjunctive Treatment of Patients with Major Depressive Disorder